Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Combination antiretroviral therapy and chronic HIV infection affect serum retinoid concentrations: longitudinal and cross-sectional assessments.

Loignon M, Brodeur H, Deschênes S, Phaneuf D, Bhat PV, Toma E.

AIDS Res Ther. 2012 Feb 1;9:3. doi: 10.1186/1742-6405-9-3.

2.

HIV-protease inhibitors alter retinoic acid synthesis.

Toma E, Devost D, Chow Lan N, Bhat PV.

AIDS. 2001 Oct 19;15(15):1979-84.

PMID:
11600826
3.

Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients.

Casado JL, Abad-Fernández M, Moreno S, Pérez-Elías MJ, Moreno A, Bernardino JI, Vallejo A.

HIV Med. 2015 Apr;16(4):240-8. doi: 10.1111/hiv.12206. Epub 2015 Jan 21.

4.

Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.

Kvale D, Ormaasen V, Kran AM, Johansson CC, Aukrust P, Aandahl EM, Frøland SS, Taskén K.

AIDS. 2006 Apr 4;20(6):813-20.

PMID:
16549964
5.

GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals.

Stapleton JT, Chaloner K, Martenson JA, Zhang J, Klinzman D, Xiang J, Sauter W, Desai SN, Landay A.

PLoS One. 2012;7(11):e50563. doi: 10.1371/journal.pone.0050563. Epub 2012 Nov 29.

6.

Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database.

Zhou J, Sirisanthana T, Kiertiburanakul S, Chen YM, Han N, Lim PL, Kumarasamy N, Choi JY, Merati TP, Yunihastuti E, Oka S, Kamarulzaman A, Phanuphak P, Lee CK, Li PC, Pujari S, Saphonn V, Law MG.

BMC Infect Dis. 2010 Dec 23;10:361. doi: 10.1186/1471-2334-10-361.

7.

Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy.

Cervero M, Agud JL, Torres R, García-Lacalle C, Alcázar V, Jusdado JJ, Moreno S.

HIV Med. 2013 Oct;14(9):556-62. doi: 10.1111/hiv.12049. Epub 2013 Jun 5.

8.

Micronutrient levels and HIV disease status in HIV-infected patients on highly active antiretroviral therapy in the Nutrition for Healthy Living cohort.

Jones CY, Tang AM, Forrester JE, Huang J, Hendricks KM, Knox TA, Spiegelman D, Semba RD, Woods MN.

J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):475-82.

PMID:
17019373
9.

Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.

Zaegel-Faucher O, Bregigeon S, Cano CE, Obry-Roguet V, Nicolino-Brunet C, Tamalet C, Dignat-George F, Poizot-Martin I.

AIDS. 2015 Jul 31;29(12):1505-10. doi: 10.1097/QAD.0000000000000650.

PMID:
26244390
10.

Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.

Kousignian I, Abgrall S, Grabar S, Mahamat A, Teicher E, Rouveix E, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

Clin Infect Dis. 2008 Jan 15;46(2):296-304. doi: 10.1086/524753.

PMID:
18171266
11.

Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.

Sánchez-Ramón S, Bellón JM, Resino S, Cantó-Nogués C, Gurbindo D, Ramos JT, Muñoz-Fernández MA.

Pediatrics. 2003 Feb;111(2):E168-75.

PMID:
12563091
12.

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B.

Lancet Infect Dis. 2014 Apr;14(4):291-300. doi: 10.1016/S1473-3099(13)70343-8. Epub 2014 Feb 11.

13.

Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation.

Kang S, Duell EA, Fisher GJ, Datta SC, Wang ZQ, Reddy AP, Tavakkol A, Yi JY, Griffiths CE, Elder JT, et al.

J Invest Dermatol. 1995 Oct;105(4):549-56.

14.

Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy.

Ndumbi P, Gillis J, Raboud J, Cooper C, Hogg RS, Montaner JS, Burchell AN, Loutfy MR, Machouf N, Klein MB, Tsoukas C; Canadian Observational Cohort (CANOC) Collaboration.

HIV Med. 2014 Mar;15(3):153-64. doi: 10.1111/hiv.12096. Epub 2013 Oct 31.

15.

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):37-46. doi: 10.1097/QAI.0b013e31819ff102.

16.

Persisting inflammation and chronic immune activation but intact cognitive function in HIV-infected patients after long-term treatment with combination antiretroviral therapy.

Pedersen KK, Pedersen M, Gaardbo JC, Ronit A, Hartling HJ, Bruunsgaard H, Gerstoft J, Ullum H, Nielsen SD.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):272-9. doi: 10.1097/QAI.0b013e318289bced.

PMID:
23392469
17.

4-Oxoretinol, a new natural ligand and transactivator of the retinoic acid receptors.

Achkar CC, Derguini F, Blumberg B, Langston A, Levin AA, Speck J, Evans RM, Bolado J Jr, Nakanishi K, Buck J, Gudas LJ.

Proc Natl Acad Sci U S A. 1996 May 14;93(10):4879-84.

18.

Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals.

Helleberg M, Kronborg G, Ullum H, Ryder LP, Obel N, Gerstoft J.

J Infect Dis. 2015 Jun 1;211(11):1726-34. doi: 10.1093/infdis/jiu669. Epub 2014 Dec 8.

PMID:
25489001
19.

The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.

Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; EuroSIDA Study in EuroCOORD.

Antivir Ther. 2012;17(7):1291-300. doi: 10.3851/IMP2407. Epub 2012 Sep 26.

PMID:
23013779
20.

Inhibition of retinoid toxicity by rat liver S9 fraction in cultured mammalian cells.

Qin S, Sirianni SR, Huang CC.

Cancer Lett. 1983 Dec;21(2):201-10.

PMID:
6686081

Supplemental Content

Support Center